| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Dabigatran-d3 targets thrombin, a key enzyme in the coagulation cascade. Dabigatran is a reversible, competitive direct thrombin inhibitor with a Ki of 4.5 nM. Dabigatran also inhibits thrombin-induced platelet aggregation with an IC50 of 10 nM.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Dabigatran-d3 is not typically used for activity assays; its primary use is as an internal standard. The biological activity of Dabigatran-d3 is expected to be similar to that of dabigatran, which inhibits thrombin with a Ki of 4.5 nM. |
| ln Vivo |
In vivo studies using Dabigatran-d3 are primarily pharmacokinetic in nature. The compound is used as an internal standard to study the pharmacokinetics of dabigatran. Deuterium-labeled compounds are used to track the parent drug and its metabolites in biological samples.
|
| Enzyme Assay |
The use of Dabigatran-d3 in in vitro experiments is primarily analytical. It is used as an internal standard in liquid chromatography-mass spectrometry (LC-MS) methods for the quantification of dabigatran in biological samples. The compound is added to samples at a known concentration, and the ratio of dabigatran to Dabigatran-d3 is used to calculate the concentration of dabigatran.
|
| Cell Assay |
In vitro cellular assays are not typically performed with Dabigatran-d3, as the compound is primarily used as an internal standard. If cellular studies were performed, they would be similar to those for dabigatran, assessing thrombin inhibition.
|
| Animal Protocol |
Dabigatran-d3 is used in pharmacokinetic studies in animals and humans. The compound is administered along with dabigatran, and blood or tissue samples are collected at various time points. The concentration of Dabigatran-d3 is measured by LC-MS.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Dabigatran-d3 are similar to those of dabigatran, as the deuterium label does not significantly alter the compound's physicochemical properties. The compound has a molecular weight of 474.53. Dabigatran-d3 is used as an internal standard in pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
Dabigatran-d3 is a stable isotope-labeled compound with a molecular weight of 474.53. It is a white to off-white solid. As a labeled compound, it is not typically used for toxicology studies; its primary use is analytical. Dabigatran-d3 is for research use only.
|
| References |
|
| Additional Infomation |
Dabigatran-d3 (BIBR 953-d3) is the deuterium-labeled form of dabigatran, a direct thrombin inhibitor. It is intended for use as an internal standard for the quantification of dabigatran by mass spectrometry. The compound has a molecular weight of 474.53. No separate clinical trials or regulatory approvals have been reported for Dabigatran-d3 itself.
|
| Molecular Formula |
C25H22D3N7O3
|
|---|---|
| Molecular Weight |
474.53
|
| Exact Mass |
474.221
|
| CAS # |
1246817-44-6
|
| Related CAS # |
Dabigatran;211914-51-1
|
| PubChem CID |
71315160
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.859
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
35
|
| Complexity |
757
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[2H]C([2H])([2H])N1C2=C(C=C(C=C2)C(=O)N(CCC(=O)O)C3=CC=CC=N3)N=C1CNC4=CC=C(C=C4)C(=N)N
|
| InChi Key |
YBSJFWOBGCMAKL-FIBGUPNXSA-N
|
| InChi Code |
InChI=1S/C25H25N7O3/c1-31-20-10-7-17(25(35)32(13-11-23(33)34)21-4-2-3-12-28-21)14-19(20)30-22(31)15-29-18-8-5-16(6-9-18)24(26)27/h2-10,12,14,29H,11,13,15H2,1H3,(H3,26,27)(H,33,34)/i1D3
|
| Chemical Name |
3-[[2-[(4-carbamimidoylanilino)methyl]-1-(trideuteriomethyl)benzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1073 mL | 10.5367 mL | 21.0735 mL | |
| 5 mM | 0.4215 mL | 2.1073 mL | 4.2147 mL | |
| 10 mM | 0.2107 mL | 1.0537 mL | 2.1073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
